Sells disposable stem cell concentration kits to physicians and develops regenerative cell therapies for people with immune, hormone-related, urinary and other conditions.
10-K for FY2025, filed Mar 20, 2026 10-K for FY2022, filed Mar 31, 2023We currently conduct substantially all of our commercial operations through CMT, which markets and sells our CaverStem® and FemCelz®…View ↗
Physicians buy the disposable kits used for procedures, and the company is generally paid when the kits are delivered.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 20, 2026We generate revenues through the sale of disposable bone marrow aspiration kits to physicians who use the kits to perform the CaverStem®…View ↗
The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the…View ↗
$6K
10-K for FY2025, filed Mar 20, 2026
$6K ↗
Physicians buy the company’s disposable kits for use in CaverStem and FemCelz procedures.
10-K for FY2022, filed Mar 31, 2023We currently conduct substantially all of our commercial operations through CMT, which markets and sells our CaverStem® and FemCelz®…View ↗
We generate revenues through the sale of disposable bone marrow aspiration kits to physicians who use the kits to perform the CaverStem®…View ↗
We generate revenues through the sale of disposable bone marrow aspiration kits to physicians who use the kits to perform the FemCelz®…View ↗
No. It lost $6M in FY2025.
10-K for FY2025, filed Mar 20, 2026
Shrinking. Revenue fell 93% in 4 years, from $87.8K in FY2021 to $6K in FY2025, about 49% a year.
Competes with Mesoblast, Longeveron, BioRestorative Therapies, and DiscGenics
10-K for FY2025, filed Mar 20, 2026Companies working in the area of regenerative medicine with regard to the disc and spine include, among others, Mesoblast, Longeveron…View ↗
Loading...